My ePortfolio Register   

Denosumab vs zoledronic acid for bone disease in newly diagnosed multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.03.17
Views: 861

Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece

Prof Terpos speaks with ecancer at the 16th International Myeloma Workshop about late breaking data from IMW 2017, assessing the efficacy and safety of denosumab compared with zoledronic Acid in newly diagnosed symptomatic myeloma patients.

Targeting RANKL, this Phase III study with denosumab met its primary endpoint of non-inferiority to zoledronic Acid in delaying time to first on-study skeletal related events in patients with newly diagnosed myeloma.

Denosumab also showed comparable overall survival and for the first time superior PFS compared with zoledronic Acid.

Renal adverse events were also greatly reduced with denosumab.

These results and the fact that denosumab can be administered subcutaneously, lead to the suggestion that it will become a new standard of care for the management of bone disease in multiple myeloma.

These findings are also discussed by Dr Raje here

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence